ArticleClinical case reports2026
Takotsubo Cardiomyopathy Secondary to Lung Transplantation Followed by Reduced Ejection Fraction Heart Failure: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Takotsubo Cardiomyopathy Secondary to Lung Transplantation Followed by Reduced Ejection Fraction Heart Failure: A Case Report.Clinical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Takotsubo cardiomyopathy (TTC) is characterized by acute, transient left ventricular systolic dysfunction with regional wall-motion abnormalities. It is a form of stress-induced cardiomyopathy and can happen due to emotional or physical stress. Lung transplantation (LTx) is a major stressor that can lead to TTC. Its presentation with reversible left ventricular dysfunction and electrocardiographic (ECG) changes can mimic acute coronary syndrome (ACS), necessitating high clinical suspicion, particularly because of its potential for serious complications. We report a case of a 23-year-old male with cystic fibrosis who underwent bilateral LTx and developed TTC during surgery with a decrease in left ventricular ejection fraction (LVEF). Postoperative management included extracorporeal membrane oxygenation (ECMO), supportive medical therapy, and recovery of cardiac function within three weeks following LTx. Remarkably, one year posttransplantation he presented with reduced LVEF (30%) and pulmonary edema in the context of prior medication non-adherence. Echocardiography at that time showed reduced LVEF without wall-motion abnormality or apical ballooning, making TTC recurrence unlikely. With re-initiation of medical treatment, LVEF improved to approximately 35%. TTC should be considered in LTx recipients who present with acute left ventricular dysfunction and possible dynamic ECG changes because it can mimic ACS. Awareness of its risk following transplantation is crucial for timely diagnosis and management. Supportive management, including mechanical circulatory support such as ECMO, is vital during the acute phase. The morbidity and mortality associated with TTC are considerable; therefore, proper monitoring and treatment are essential. To our knowledge, TTC during LTx followed by late reduced LVEF during follow-up has rarely been reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.